Physician profile
Edward C Travis
NPI 1801909700
$1,073.57
in general payments reported to CMS, 2019-2025
19 companies · $96.18 in 2025
The $96.18 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $169 · 2020: $24.32 · 2021: $157 · 2022: $242 · 2023: $180 · 2024: $205 · 2025: $96.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $480.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $260.80 | 2019-2025 | Breztri, Airsupra |
| Lilly USA, LLC | $122.36 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $112.32 | 2019-2025 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.73 | 2021-2023 | Tradjenta, Synjardy, Jardiance |
| Dexcom, INC. | $82.30 | 2021-2022 | |
| Mylan Specialty L.P. | $61.00 | 2019-2024 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $50.27 | 2022 | |
| Amgen INC. | $39.53 | 2019 | |
| Vanda Pharmaceuticals INC. | $36.21 | 2025 | Fanapt |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.05 | 2019-2021 | |
| Viatris Specialty LLC | $28.75 | 2025 | Yupelri |
| Xeris Pharmaceuticals, INC. | $23.68 | 2023 | Gvoke Hypopen |
| Grifols USA, LLC | $21.25 | 2024 | Prolastin-C Liquid |
| Abbvie INC. | $19.00 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.66 | 2024 | Caplyta |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $17.89 | 2024 | |
| Melinta Therapeutics, LLC | $13.92 | 2019 | |
| Idorsia Pharmaceuticals US INC | $13.14 | 2023 | Quviviq |
| Genentech USA, INC. | $11.71 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Travis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.